Tetrabenazine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Tetrabenazine

Tetrabenazine (marketed under the trade names Nitoman® in Canada and Xenazine® in New Zealand and some parts of Europe - also available in the USA as an orphan drug) is a dopamine-depleting drug that is closely related to the antipsychotics and works similarly, though its action is subtly different and it is not necessarily considered an antipsychotic itself. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Common uses

Tetrabenazine is used as a treatment, but not a cure for hyperkinetic movement disorders such as:

  • Huntington's Disease - specificially the chorea associated with it
  • Tourette's Syndrome and other tic disorders
  • Tardive dyskinesia, a serious and sometimes irreversible side effect of long-term use of many antipsychotics, mainly typical antipsychotics

Side Effects

Because tetrabenazine is closely related to the antipsychotics, many of its side effects are similar. Some of these include:

  • Depression - the most common side effect, reported in roughly 15% of those who take the medication
  • Dizziness/drowsiness
  • Akathisia (aka "restless pacing" - an inability to keep still, with intense anxiety when forced to do so)

Unlike many of the antipychotics, tetrabenazine is not known to cause Tardive dyskinesia, and in fact can be an effective treatment for the antipsychotic-induced movement disorder.

Warnings

  • Because of the relatively high incidence of depression, it has been recommended that people with a history of depression avoid taking tetrabenazine. Research into this is ongoing however, and this warning may be dropped in the future.

Read more at Wikipedia.org


[List your site here Free!]


New Data Reported on Tetrabenazine for the Treatment of Pediatric Hyperkinetic Movement Disorders
From Business Wire, 4/15/05

MIAMI BEACH, Fla. -- Findings Presented at 57th Annual Meeting of the American Academy of Neurology

Clinical study investigators concluded that tetrabenazine was an effective and well-tolerated treatment for severe hyperkinetic movement disorders among children who are resistant to other medications, according to new data presented today at the 57th Annual Meeting of the American Academy of Neurology in Miami Beach.

"This is one of the largest reported studies of children treated with tetrabenazine," said Steven J. Frucht, MD, Assistant Professor of Neurology, Neurological Institute of New York, Columbia University Medical, Center for Parkinson's Disease and Other Movement Disorders, and lead investigator of the study. "We are encouraged by the fact that nearly three quarters of children treated with tetrabenazine experienced a reduction in their involuntary movements."

Study Design and Results

Over the course of 18 years, 30 children aged 18 years and younger were treated with tetrabenazine at Columbia University Medical Center for a variety of hyperkinetic movement disorders, including chorea, dystonia, and Tourette Syndrome or tics. The study was approved by the medical center's institutional review board, and neither the study nor the investigators were supported by Prestwick.

A retrospective chart review was conducted to assess the efficacy and tolerability of tetrabenazine among these patient populations. Twenty-eight patients (93%) had tried other medications without adequate relief prior to being placed on tetrabenazine. On average, patients were treated with a total dose of 150.9 mg/d (4.9 mg/kg/d) for 1.3 years.

Twenty-two of the 30 patients (73%) experienced a reduction in movements (as assessed by the examining physician) after starting tetrabenazine. Sixteen patients continued tetrabenazine along with at least one other medication to control movements, while movements were sufficiently controlled with tetrabenazine alone in six patients. Side effects, which were ameliorated with a reduction in dose, were experienced in nineteen patients (63%), including sedation (30%), behavioral changes (20%), depression (10%), worsening of movements (6%), nausea (3%) and parkinsonism (3%). Nine patients (30%) discontinued tetrabenazine due to behavior changes (3), sedation (3), worsening or lack of improvement in movements (2) and major depression (1).

"The results of this pediatric study support earlier findings in adults that suggest tetrabenazine may be an effective and well-tolerated treatment option for severe pediatric hyperkinetic movement disorders," said Dr. Frucht. "Similarly, side effects were typically dose-dependent, and we did not observe tardive dyskinesia in our patient population."

Tetrabenazine

Tetrabenazine is available in some European markets and Australia as XENAZINE(R) and in Canada as NITOMAN(R) for the treatment of hyperkinetic movement disorders. Tetrabenazine is not FDA-approved for marketing in the United States. Side effects can include drowsiness, insomnia, akathisia and depression.

Prestwick Pharmaceuticals

Prestwick Pharmaceuticals, Inc. is a product-focused specialty pharmaceutical company engaged in the development and commercialization of drugs with high commercial potential and relatively low development risk that target chronic diseases of the central nervous system. To date, the company has in-licensed rights relating to product candidates in clinical development for the treatment of CNS disorders, including chorea associated with Huntington's Disease, Parkinson's disease and schizophrenia.

In October 2004, Prestwick announced the results of its Phase III study of tetrabenazine for chorea associated with Huntington's Disease. The study was conducted in adults only. The company anticipates filing a New Drug Application (NDA) for tetrabenazine with the U.S. Food and Drug Administration (FDA) in the near future. Prestwick was granted both fast track and orphan designation by the FDA for tetrabenazine.

COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group

Return to Tetrabenazine
Home Contact Resources Exchange Links ebay